You have free access to this content

British Journal of Clinical Pharmacology

Cover image for Vol. 75 Issue 2

February 2013

Volume 75, Issue 2

Pages i–ii, 301–584

  1. Issue Information

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
  2. Editors’ report

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      Editors’ Report, 2012 (pages 301–302)

      Yoon K. Loke, Adam F. Cohen, Albert Ferro, Lionel D. Lewis, James M. Ritter and Andrew A. Somogyi

      Article first published online: 10 JAN 2013 | DOI: 10.1111/bcp.12046

  3. Medical cannabidiol – is there anything it can't do?

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      Cannabidiol as potential anticancer drug (pages 303–312)

      Paola Massi, Marta Solinas, Valentina Cinquina and Daniela Parolaro

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04298.x

    2. You have free access to this content
      Is the cardiovascular system a therapeutic target for cannabidiol? (pages 313–322)

      Christopher P. Stanley, William H. Hind and Saoirse E. O'Sullivan

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04351.x

    3. You have free access to this content
      Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? (pages 323–333)

      Javier Fernández-Ruiz, Onintza Sagredo, M. Ruth Pazos, Concepción García, Roger Pertwee, Raphael Mechoulam and José Martínez-Orgado

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04341.x

  4. Reviews

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      Pharmacogenomics of warfarin in populations of African descent (pages 334–346)

      Guilherme Suarez-Kurtz and Mariana R. Botton

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04354.x

    2. You have free access to this content
    3. You have free access to this content
  5. Education

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      Online learning applied to a course on rational therapeutics: an international comparison between final year students of two medical schools (pages 373–380)

      Robert Likic, Casey White, Sandro Cinti, Joel Purkiss, Joseph Fantone, Chris Chapman, Luka Bielen, Igor Francetic and Cary Engleberg

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04370.x

  6. Clinical trials

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men (pages 381–391)

      Graham Scott, Irfan Ahmad, Katy Howard, David MacLean, Cristina Oliva, Steve Warrington, Darren Wilbraham and Paul Worthington

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04385.x

    2. You have free access to this content
      Insulin at normal physiological levels does not prolong QTc interval in thorough QT studies performed in healthy volunteers (pages 392–403)

      Jorg Taubel, Ulrike Lorch, Georg Ferber, Jatinder Singh, Velislav N. Batchvarov, Irina Savelieva and A. John Camm

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04376.x

    3. You have free access to this content
      An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UVB-inflamed and normal skin (pages 404–414)

      Klaus Schaffler, Peter Reeh, W. Rachel Duan, Andrea E. Best, Ahmed A. Othman, Connie R. Faltynek, Charles Locke and Wolfram Nothaft

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04377.x

  7. Pharmacodynamics

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers (pages 415–422)

      Hitoshi Ando, Kentarou Ushijima, Keiko Hosohata, Tetsuo Saito and Akio Fujimura

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04358.x

    2. You have free access to this content
  8. Pharmacokinetics

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers (pages 431–439)

      Varun Garg, Gurudatt Chandorkar, Yijun Yang, Nathalie Adda, Lindsay McNair, Katia Alves, Frances Smith and Rolf P. G. van Heeswijk

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04345.x

    2. You have free access to this content
      The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4 (pages 440–449)

      Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, Takeshi Kadokura, Marten Heeringa, Roelof Mol, Charlotte Eltink and Hartmut Onkels

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04346.x

    3. You have free access to this content
      Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers (pages 450–462)

      Laurie P. Volak, Michael J. Hanley, Gina Masse, Suwagmani Hazarika, Jerold S. Harmatz, Vladimir Badmaev, Muhammed Majeed, David J. Greenblatt and Michael H. Court

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04364.x

    4. You have free access to this content
    5. You have full text access to this OnlineOpen article
      Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects (pages 476–487)

      Charles Frost, Jessie Wang, Sunil Nepal, Alan Schuster, Yu Chen Barrett, Rogelio Mosqueda-Garcia, Richard A. Reeves and Frank LaCreta

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04369.x

  9. Drug interactions

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling (pages 488–496)

      Jackie C. Bloomer, Mike Nash, Alison Webb, Bruce E. Miller, Aili L. Lazaar, Claire Beaumont and William J. Guiney

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04352.x

    2. You have free access to this content
      Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity (pages 497–506)

      Barbara J. Brennan, Zhi-Xin Xu and Joseph F. Grippo

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04373.x

    3. You have free access to this content
      Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin (pages 507–521)

      Lot A. Devriese, Petronella (Els) O. Witteveen, Jantien Wanders, Kenneth Law, Geoff Edwards, Larisa Reyderman, William Copalu, Fuping Peng, Serena Marchetti, Jos H. Beijnen, Alwin D. R. Huitema, Emile E. Voest and Jan H. M. Schellens

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04381.x

  10. Pharmacogenetics

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients (pages 522–534)

      Xiaojing Xu, Lifang Han, Li Duan, Yingchun Zhao, Huaping Yang, Boting Zhou, Rui Ma, Ruixia Yuan, Honghao Zhou and Zhaoqian Liu

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04379.x

  11. Drug safety

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have full text access to this OnlineOpen article
      First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials (pages 535–548)

      Joerg J. Moehrle, Stephan Duparc, Christoph Siethoff, Paul L. M. van Giersbergen, J. Carl Craft, Sarah Arbe-Barnes, Susan A. Charman, Maria Gutierrez, Sergio Wittlin and Jonathan L. Vennerstrom

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04368.x

    2. You have free access to this content
      Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers (pages 549–564)

      Corina Loghin, Harry Haber, Charles M. Beasley Jr, Prajakti A. Kothare, Lynnette Kauffman, John April, Ling Jin, Albert J. Allen and Malcolm I. Mitchell

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04382.x

  12. Letters to the editors

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
      Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome (pages 565–568)

      John Coutsouvelis, Meredith Wiseman, Lisa Hui, Susan Poole, Michael Dooley, Sushrut Patil, Sharon Avery, Andrew Wei and Andrew Spencer

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04355.x

    2. You have free access to this content
      Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring (pages 569–570)

      Paul K. L. Chin, Murray L. Barclay and Evan J. Begg

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04408.x

    3. You have free access to this content
      Response to the letter by Dr Chin and co-workers (page 571)

      Sebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, Gerhard Nehmiz, Ute Lemke, Wolfgang Timmer and Paul A. Reilly

      Article first published online: 10 JAN 2013 | DOI: 10.1111/j.1365-2125.2012.04407.x

  13. Book reviews

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
    2. You have free access to this content
  14. Abstracts

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content
  15. Mandarin translations section

    1. Top of page
    2. Issue Information
    3. Editors’ report
    4. Medical cannabidiol – is there anything it can't do?
    5. Reviews
    6. Education
    7. Clinical trials
    8. Pharmacodynamics
    9. Pharmacokinetics
    10. Drug interactions
    11. Pharmacogenetics
    12. Drug safety
    13. Letters to the editors
    14. Book reviews
    15. Abstracts
    16. Mandarin translations section
    1. You have free access to this content

SEARCH

SEARCH BY CITATION